Could KL-6 levels in COVID-19 help to predict lung disease?

Introducing an index to predict lung involvement deficiency in hypertensive patients with COVID-19

INTERSTITIAL LUNG DISEASE Circulating KL-6 levels in patients with drug induced pneumonitis

Background: The circulating level of KL-6/MUC1 is a sensitive marker for various interstitial lung diseases. Previous case reports have suggested that KL-6 may also be increased in some patients with drug induced pneumonitis. A study was undertaken to determine whether serum KL-6 could be a marker for particular types of drug induced pneumonitis. Methods: The findings of high resolution compute...

COVID-19 and dermatologists (6)

The sixth article of COVID-19 review series is published while the virus is invading the world. In this issue, lastest findings about skin manifestations of this disease, skin diseases course, also diagnosis and treatment of COVID-19 and skin reactions due to vaccines are presented.

Digital Clubbing Is Associated with Higher Serum KL-6 Levels and Lower Pulmonary Function in Patients with Interstitial Lung Disease

Background Although digital clubbing is a common presentation in patients with interstitial lung disease (ILD), little has been reported regarding its role in assessing patients with ILD. This study evaluated patients with ILD for the presence of clubbing and investigated its association with clinical data. Methods We evaluated patients with ILD who visited the teaching hospital at which the ...

Ageing and long-term smoking affects KL-6 levels in the lung, induced sputum and plasma

BACKGROUND KL-6 is a high-molecular-weight glycoprotein classified as a human MUC1 mucin. It was hypothesized that KL-6 could be detectable in the circulating blood and especially in airway secretions in lung diseases associated with mucus production such as chronic obstructive pulmonary disease (COPD). Additional aims of this study were to investigate whether the levels of KL-6 in plasma and s...